99 related articles for article (PubMed ID: 33065443)
1. Generation, optimization and characterization of novel anti-prion compounds.
Altieri A; Spiridonov EA; Sivtzev SI; Ishibashi D; Biggi S; Nishida N; Biasini E; Kurkin AV
Bioorg Med Chem; 2020 Nov; 28(21):115717. PubMed ID: 33065443
[TBL] [Abstract][Full Text] [Related]
2. A Small-Molecule Inhibitor of Prion Replication and Mutant Prion Protein Toxicity.
Massignan T; Sangiovanni V; Biggi S; Stincardini C; Elezgarai SR; Maietta G; Andreev IA; Ratmanova NK; Belov DS; Lukyanenko ER; Belov GM; Barreca ML; Altieri A; Kurkin AV; Biasini E
ChemMedChem; 2017 Aug; 12(16):1286-1292. PubMed ID: 28722340
[TBL] [Abstract][Full Text] [Related]
3. Identification of Anti-prion Compounds using a Novel Cellular Assay.
Imberdis T; Heeres JT; Yueh H; Fang C; Zhen J; Rich CB; Glicksman M; Beeler AB; Harris DA
J Biol Chem; 2016 Dec; 291(50):26164-26176. PubMed ID: 27803163
[TBL] [Abstract][Full Text] [Related]
4. Combining autophagy stimulators and cellulose ethers for therapy against prion disease.
Abdulrahman BA; Tahir W; Doh-Ura K; Gilch S; Schatzl HM
Prion; 2019 Jan; 13(1):185-196. PubMed ID: 31578923
[TBL] [Abstract][Full Text] [Related]
5. In silico strategies on prion pathogenic conversion and inhibition from PrP
Pagadala NS; Syed K; Bhat R
Expert Opin Drug Discov; 2017 Mar; 12(3):241-248. PubMed ID: 28118747
[TBL] [Abstract][Full Text] [Related]
6. A sensitive filter retention assay for the detection of PrP(Sc) and the screening of anti-prion compounds.
Winklhofer KF; Hartl FU; Tatzelt J
FEBS Lett; 2001 Aug; 503(1):41-5. PubMed ID: 11513851
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel fluorescent probes preventing PrP
Zaccagnini L; Brogi S; Brindisi M; Gemma S; Chemi G; Legname G; Campiani G; Butini S
Eur J Med Chem; 2017 Feb; 127():859-873. PubMed ID: 27842893
[TBL] [Abstract][Full Text] [Related]
8. Host Determinants of Prion Strain Diversity Independent of Prion Protein Genotype.
Crowell J; Hughson A; Caughey B; Bessen RA
J Virol; 2015 Oct; 89(20):10427-41. PubMed ID: 26246570
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 2-aminothiazoles as potent antiprion compounds.
Ghaemmaghami S; May BC; Renslo AR; Prusiner SB
J Virol; 2010 Apr; 84(7):3408-12. PubMed ID: 20032192
[TBL] [Abstract][Full Text] [Related]
10. Strain-Dependent Prion Infection in Mice Expressing Prion Protein with Deletion of Central Residues 91-106.
Uchiyama K; Miyata H; Yamaguchi Y; Imamura M; Okazaki M; Pasiana AD; Chida J; Hara H; Atarashi R; Watanabe H; Kondoh G; Sakaguchi S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019549
[TBL] [Abstract][Full Text] [Related]
11. Prion Infectivity Plateaus and Conversion to Symptomatic Disease Originate from Falling Precursor Levels and Increased Levels of Oligomeric PrPSc Species.
Mays CE; van der Merwe J; Kim C; Haldiman T; McKenzie D; Safar JG; Westaway D
J Virol; 2015 Dec; 89(24):12418-26. PubMed ID: 26423957
[TBL] [Abstract][Full Text] [Related]
12. Identification of compounds inhibiting prion replication and toxicity by removing PrP
Biggi S; Pancher M; Stincardini C; Luotti S; Massignan T; Dalle Vedove A; Astolfi A; Gatto P; Lolli G; Barreca ML; Bonetto V; Adami V; Biasini E
J Neurochem; 2020 Jan; 152(1):136-150. PubMed ID: 31264722
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.
Ertmer A; Gilch S; Yun SW; Flechsig E; Klebl B; Stein-Gerlach M; Klein MA; Schätzl HM
J Biol Chem; 2004 Oct; 279(40):41918-27. PubMed ID: 15247213
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
Viruses; 2019 May; 11(5):. PubMed ID: 31083283
[TBL] [Abstract][Full Text] [Related]
15. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
16. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
17. Scrapie infection of prion protein-deficient cell line upon ectopic expression of mutant prion proteins.
Maas E; Geissen M; Groschup MH; Rost R; Onodera T; Schätzl H; Vorberg IM
J Biol Chem; 2007 Jun; 282(26):18702-10. PubMed ID: 17468101
[TBL] [Abstract][Full Text] [Related]
18. Transmissible and genetic prion diseases share a common pathway of neurodegeneration.
Hegde RS; Tremblay P; Groth D; DeArmond SJ; Prusiner SB; Lingappa VR
Nature; 1999 Dec; 402(6763):822-6. PubMed ID: 10617204
[TBL] [Abstract][Full Text] [Related]
19. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
20. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
